Compare Amylx Pharmaceuticals Inc (AMLX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Zscaler Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.49 (market cap $2.64B), while Zscaler Inc trades at $176.92 (market cap $28.87B). The key difference: Zscaler Inc is far larger — about 10.9× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| AMLX | ZS | |
|---|---|---|
Market Cap | $2.64B | $28.87B |
Sector | Health | Technology |
52-Week High | $24.19 | $336.27 |
52-Week Low | $7.82 | $118.05 |
Enterprise Value | $2.39B | $27.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.35, up 3.0% today, with a bullish technical signal from moving averages. The company reported a net loss of $144.74M in 2025, with negative ROE and ROA, but maintains a strong cash position of $250.8M extending into 2028. Key near-term catalyst is the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, which could drive significant stock movement.
The investment case hinges on successful clinical outcomes; a positive readout may support the consensus price target of $30.00, but persistent losses and high P/B ratio of 11.02 pose risks. Analyst sentiment is overwhelmingly bullish with 91% buy ratings, though recent earnings misses highlight execution challenges.
Zscaler (ZS) trades at $176.94, up 0.15% with strong bullish technical signals and positive analyst sentiment. The stock shows consistent revenue growth from $1.1B in 2022 to $2.67B in 2025, though it remains unprofitable with a -2.44% net margin. Recent earnings beats and leadership in Gartner Magic Quadrant for SASE platforms highlight operational strength. Current price sits near resistance at $177 with RSI indicating overbought conditions.
Outlook remains positive with 79% analyst buy ratings and $191.81 consensus target, but risks include negative profitability, high valuation multiples (P/S 8.94), and projected negative cash flow in 2026. The cybersecurity leader benefits from AI-driven security demand but faces execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
